Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT. But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders.

Mayo Clinic develops AI capable of substantially improving dementia diagnoses
With the software's help, readers are up to three times more accurate and interpretations are nearly twice as fast.
FDA approves expanded use of PET imaging agent
The product's updated indications include quantification and long-term monitoring of amyloid plaques on imaging.
'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer
The agent “exhibits powerful tumor delineation” in challenging cases of determining cancer subtypes, and could potentially lead to more personalized, effective treatment strategies.
Industry partnership set to advance research on theranostics
The deal will create a Therapy Command Center to support the study and use of theranostics across Massachusetts General Hospital and its affiliated centers in bordering states.
SNMMI unveils its 2025 Image of the Year
The designation was awarded to a research team from China, who analyzed the efficacy of a novel radiotracer developed to target expression of the PD-L1 protein in suspected head and neck cancers.

New prostate cancer PET imaging agent officially available for commercial use

Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.

Folate-based radiopharmaceuticals could improve detection of gliomas

According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.

Do clinicians want radiologists' management advice? Interviews shed some light on 'unwanted' recommendations

Clinicians only want the information they need to make treatment decisions, rather than advice on what actions they should take, the survey found.

American College of Radiology, nuclear medicine society urge CMS to fix years-old billing code mistakes

SNMMI and ACR are pushing the agency to make modifications retroactive, so specialists can still claim lost revenues impacted by the error.

Will PET imaging be covered alongside new Alzheimer's drugs? CMS dodges topic in new coverage decision

The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.

FDA clears GE HealthCare’s AI solution for enhancing PET/CT image quality

Precision DL was engineered using a deep neural network, trained with thousands of images, the Chicago-based company said May 30.

Imaging advocacy group slams ‘extremely restrictive’ Medicare coverage determination

A Medicare Administrative Contractor is wrongly rejecting coverage of PET imaging in cases of infection/inflammation, SNMMI reported recently.

FDA approves new PSMA-targeted PET imaging agent for prostate cancer

Blue Earth Diagnostics said this is the first and only PSMA-targeted imaging agent developed with its proprietary radiohybrid technology.

Nuclear Medicine

Mayo Clinic develops AI capable of substantially improving dementia diagnoses

FDA approves expanded use of PET imaging agent

'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer

Industry partnership set to advance research on theranostics

SNMMI unveils its 2025 Image of the Year